Drug

Base Edited Natural Killer Cells NK510 clinical trials

Also written NK510.

studies test it: 4
open now: 3
in phase 3: 0
first study started: 2022

Keep track of what changes. Save the Base Edited Natural Killer Cells NK510 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

NK510: 3

Studies by the year they started

4 studies that test it; most in 2025 (2)

Studies that test Base Edited Natural Killer Cells NK510, by start year
Year	Studies
2022	1
2025	2
2026	1

By phase

A phase 1/2 study counts in both.

Early Phase 1: 3
Phase 1: 1
Phase 2: 1

What it is tested for

Each study’s main condition, where its own words name it.

Stomach Neoplasms: 1
Osteosarcoma: 1
Lupus Erythematosus, Systemic: 1

Who runs them

Industry 3 · Other 1

Base Therapeutics (Shanghai) Co., Ltd. (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)

Often tested with

Tested in the same studies.

Izalontamab brengitecan (1) · CVL006 (1) · KXV01 (1) · MT027 (1) · QH101 (1) · META10 (1) · TAEST1901 (1) · TCN 201 (1)

Studies

Open first, then newest update. How each study uses Base Edited Natural Killer Cells NK510 is read from its arms, and is right about nine times in ten.

Testing it · 4

Given in every arm · 2 — Base Edited Natural Killer Cells NK510 is usual care beside what is tested